AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)
Launchavutometinib potassium and defactinib hydrochloride
NDAORALCAPSULE, TABLETPriority Review
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
0/100
Mechanism of Action
MEK1 inhibitor. Avutometinib induces the formation of inactive RAF/MEK complexes and prevents phosphorylation of MEK1/2 by RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Avutometinib inhibited MEK1/2 and ERK1/2 phosphorylation and proliferation of tumor cell lines…
Indications (1)
Loss of Exclusivity
LOE Date
Dec 29, 2042
204 months away
Patent Expiry
Dec 29, 2042
Exclusivity Expiry
May 8, 2030